Supplementary Materials for

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles

Abdullah M. Syed^{1,2}, Alison Ciling^{1,2}, Mir M. Khalid¹, Bharath Sreekumar¹, Pei-Yi Chen¹, G.

Renuka Kumar¹, Ines Silva³, Bilal Milbes³, Noah Kojima³, Victoria Hess³, Maria Shacreaw³,

Lauren Lopez³, Matthew Brobeck³, Fred Turner³, Lee Spraggon³, Taha Y. Taha¹, Takako Tabata¹,

Irene P. Chen¹, Melanie Ott^{1,4} and Jennifer A. Doudna^{1,2,5-9}

Correspondence to: melanie.ott@gladstone.ucsf.edu; doudna@berkeley.edu

This PDF file includes:

Materials and Methods Supplementary Text Figs. S1 Tables S1 to S5

Materials and Methods

Cloning for plasmids encoding structural proteins: pcDNA3.1 backbone plasmids were generated encoding N, and M-IRES-E. Sequences for E, M and N were PCR amplified from codon optimized plasmids were gifts from Nevan Krogan (Addgene plasmid # 141385, 141386, 141391,). pcDNA3.1-SARS2-Spike was a gift from Fang Li (Addgene plasmid # 145032). Site directed mutagenesis (NEB) was used to remove the C9-tag and introduce the D614G mutation. Delta and Omicron structural protein were cloned ligating eBlocks (IDT) gene fragments following NEBuilder HiFi DNA (NEB E2621L) Assembly Reaction Protocol. SC2-VLP production: For a 24-well, plasmids CoV2-N (0.67), CoV2-M-IRES-E (0.33), CoV-2-Spike (0.006) and Luc-PS9 (1.0) at indicated mass ratios for a total of 1 µg of DNA were diluted in 50 µL Opti-MEM. 3 µg PEI was diluted in 50 µL Opti-MEM and added to plasmid dilution quickly to complex the DNA. Transfection mixture was incubated for 20 minutes at room temperature and then added dropwise to 293T cells in 0.5 mL of DMEM containing fetal bovine serum and penicillin/streptomycin. Media was changed after 24 hours of transfection and At 48 hours post-transfection, VLP containing supernatant was collected and filtered using a 0.45 µm syringe filter. For other culture sizes, the mass of DNA used was 1 µg for 24-well, 4 µg for 6-well, 20 μg for 10-cm plate and 40 μg for 15-cm plate. Opti-MEM volumes were 100 μL, 400 μ L, 1 mL and 3 mL respectively and PEI was always used at 3:1 mass ratio. Luciferase readout: In each well of a clear 96-well plate 50 µL of SC2-VLP containing supernatant was added to 50 µL of cell suspension containing 50 000 receiver cells (293T

ACE2/TMPRSS2). Cells were allowed to attach and take up VLPs overnight. Next day, supernatant was removed and cells were lysed in 20 µL passive lysis buffer (Promega) for 15

minutes at room temperature with gentle rocking. Lysates were transferred to an opaque white 96-well plate and 30 μ L of reconstituted luciferase assay buffer was added and mixed with each lysate. Luminescence was measured immediately after mixing using a TECAN plate reader with no attenuation and a luminescence integration time of 1 s.

Western blot and Imaging: Cells were lysed in RIPA buffer (Thermo Scientific[™] 89900) and lysates were collected after centrifugation. Laemmli loading buffer (1x final) and dithiothreitol (DTT, 40 mM final) was added to lysates and heated for 95°C for 5 minutes to lyse denature proteins. Samples were loaded onto 4-20% gradient gels (Biorad 567-1094) and transferred to a PVDF membrane (Biorad). Membrane was blocked in 10% NFDM and stained with primary antibody: anti-N (abcam ab273434, 1:500 dilution), anti-S (abcam ab272504, 1:1000), anti-GAPDH (Cell signaling D16H11), 1:5000) for 4 hours at room temperature or O/N at 4°C. Blots were rinsed with TBS-T three times for 10 minutes each and stained with secondary (abcam ab205719 (mouse), 1:5000; Bethyl A120-201P(Rabbit)). Imaged using pierce chemiluminescence kit.

Cell lines: Cells were maintained in a humidified incubator at 37°C in 5% CO2 in the indicated media and passaged every 3-4 days. 293T cells were obtained from ATCC and maintained in DMEM with 10% FBS and 1% penicillin/streptomycin.. 293T cells stably co-expressing ACE2 and TMPRSS2 were generated through sequential transduction of 293T cells with TMPRSS2-encoding (generated using Addgene plasmid #170390, a gift from Nir Hacohen and ACE2-encoding (generated using Addgene plasmid #154981, a gift from Sonja Best) lentiviruses and selection with hygromycin (250 µg/mL) and blasticidin (10 µg/mL) for 10 days, respectively. ACE2 and TMPRSS2 expression was verified by western blot.

Neutralization Assay: Each heat inactivated serum sample was serially diluted from 1:20 to 1:20480 dilution in complete DMEM media prior to incubation (1hr at 37°C) with 40µL VLP with total volume of 50µL, then plated onto receiver cells (50000 293T ACE2-TMPRSS2 cells). 24hr later luciferase readout was taken. Neutralization (NT50) was estimated by interpolating the dilution of serum at which 50% infectivity was reduced.

Serum samples: Serum samples from individuals not exposed to SARS-CoV-2 (pre-COVID, control), exposed to SARS-CoV-2 (post-COVID), and those vaccinated with either two doses of elasomeran (Moderna), two doses of tozinameran (Pfizer/BioNTech) vaccine or one dose of Johnson & Johnson vaccine were collected through a clinical trial led by Curative (Supplementary Table 5). Post-COVID samples reflect non vaccinated participant samples that were collected within 4-6 weeks of the original positive test and were negative by PCR at the time of serum collection. Serum from vaccinated participants was collected 4-6 weeks post vaccination following final dose. The clinical trial protocol was approved by Advarra under Pro00054108 for a study designed to investigate immune escape by SARS-CoV-2 variants. The trial has been submitted to clinicaltrials.gov registry (NCT ID pending, Unique Protocol ID: PTL-2021-0007). Sample specimens were collected from adult individuals aged 18 to 50 years who either had been vaccinated for COVID-19 and/or had a history of COVID-19. Vulnerable populations were excluded from enrollment. Patients signed consent forms held by Curative. Participants were enrolled from individuals that tested with Curative in Los Angeles County and were sent an IRB-approved email enrollment script. Those who were interested were contacted by the Curative Clinical Trials research team (CITI trained) and those who consented to the study were scheduled for sample collection by a clinician who went to their residence. Participants

underwent a standard venipuncture procedure. Briefly, licensed phlebotomists collected a maximum of 15 ml whole blood. Once collected, the sample was left at ambient temperature for 30–60 min to coagulate, then was centrifuged at 2200–2500 rpm for 15 min at room temperature. Samples were then placed on ice until delivered to the laboratory site where the serum was aliquoted to appropriate volumes for storage at -80 °C until use. A quantitative SARS-CoV-2 IgG ELISA was performed on serum specimens (EuroImmun, Anti-SARS-CoV-2 ELISA (IgG), 2606–9621G, New Jersey). To quantify SARS-CoV-2 IgG antibodies, an S1-specific monoclonal IgG antibody with no known cross-reactivity to the S2 domain of the spike protein was used as a reference antibody. A standard curve was developed using a monoclonal IgG antibody targeting the S1 antigen of SARS-CoV-2 at different concentrations with a polynomial regression curve-fitting model. The standard curve was used to calculate the sample IgG antibody concentration. Serum samples were heat inactivated at 56°C for 30 mins prior to use in VLP assays. Pre-COVID sera was pooled into one sample.







Fig. S2. Comparison of S-variants using pseudotyped lentivirus and VLPs. Luciferase signal from cells transduced using S-pseudotyped lentiviruses or VLPs. Delta and Omicron have opposite trends in infectivity in these two systems.

Table S1.

List of mutations used in each S variant divided by domains.

	NTD	RBD	СТД
B.1			D614G
B.1.1			D614G
Delta	A67V, G142D, E156G,	L452R, T478K	D614G, P681R, D950N
	Δ157-158		
Omicron	A67V, Δ69-70, T95I,	G339D, S371L, S373P, S375F,	T547K, D614G, H655Y,
	G142D, Δ143-145, Δ211,	K417N, N440K, G446S,	N679K, P681H, N764K,
	L212I, ins214-EPE	S477N, T478K, E484A, Q493K,	D796Y, N856K, Q954H,
		G496S, Q498R, N501Y, Y505H	N969K, L981F
OmC1	A67V, ∆69-70, T95I,	K417N, G496S, Q498R, N501Y	T547K, D614G, H655Y,
	G142D, Δ143-145, Δ211,		N679K, P681H, N764K,
	L212I, ins214-EPE		D796Y, N856K, Q954H,
			N969K, L981F
OmC3	A67V, ∆69-70, T95I,	N440K, G446S, G496S, Q498R	T547K, D614G, H655Y,
	G142D, Δ143-145, Δ211,		N679K, P681H, N764K,
	L212I, ins214-EPE		D796Y, N856K, Q954H,
			N969K, L981F

Table S2.

List of mutations used in each N variant divided by domains.

	NTD	SR	linker	CTD
B.1				
B.1.1		R203K, G204R		
Delta	D63G	R203M	G215C	D377Y
Omicron	P13L, Δ31-33,	R203K, G204R		
	D63G			

Table S3.

List of mutations used in each M variant.

B.1	
B.1.1	
Delta	I82T
Omicron	D3G, Q19E, A63T

Table S4.

List of mutations used in each E variant.

B.1	
B.1.1	
Delta	
Omicron	Т9І

Table S5.

Serum samples from clinical trial participants used in VLP assays in this study.

Subject ID	ELISA Status	Total IgG (ug/ml)	Sample Type
CUR01	Negative	/	pre-COVID serum
CUR02	Negative	/	pre-COVID serum
CUR03	Negative	/	pre-COVID serum
CUR04	Negative	/	pre-COVID serum
CUR05	Negative	/	pre-COVID serum
PC0002	Positive	4.45	post-COVID serum
PC0003	Positive	0.44	post-COVID serum
PC0006	Positive	2.29	post-COVID serum
PC0007	Positive	1.19	post-COVID serum
PC0008	Positive	2.16	post-COVID serum
PC0009	Positive	1.19	post-COVID serum
PC0011	Positive	39.8	post-COVID serum
PC0013	Positive	1.03	post-COVID serum
PF0002	Positive	9.67	Pfizer vaccinee serum - 2 doses
PF0004	Positive	9.32	Pfizer vaccinee serum - 2 doses
PF0005	Positive	9.36	Pfizer vaccinee serum - 2 doses
PF0006	Positive	5.05	Pfizer vaccinee serum - 2 doses
PF0007	Positive	8.85	Pfizer vaccinee serum - 2 doses
PF0009	Positive	8.21	Pfizer vaccinee serum - 2 doses
PF0011	Positive	9.66	Pfizer vaccinee serum - 2 doses
PF0012	Positive	7.01	Pfizer vaccinee serum - 2 doses
PF0013	Positive	6.41	Pfizer vaccinee serum - 2 doses
PF0016	Positive	1.79	Pfizer vaccinee serum - 2 doses
PF0017	Positive	7.72	Pfizer vaccinee serum - 2 doses
M0002	Positive	91.77	Moderna vaccinee serum - 2 doses
M0003	Positive	14.5	Moderna vaccinee serum - 2 doses
M0004	Positive	71.94	Moderna vaccinee serum - 2 doses
M0005	Positive	9.88	Moderna vaccinee serum - 2 doses
M0006	Positive	8.5	Moderna vaccinee serum - 2 doses
M0007	Positive	10.5	Moderna vaccinee serum - 2 doses
M0008	Positive	21.38	Moderna vaccinee serum - 2 doses
M0009	Positive	10.2	Moderna vaccinee serum - 2 doses
M0010	Positive	15.65	Moderna vaccinee serum - 2 doses

M0011	Positive	15.08	Moderna vaccinee serum - 2 doses
JJ0002	Positive	1.09	J+J vaccinee serum - 1 dose
JJ0003	Positive	1.63	J+J vaccinee serum - 1 dose
JJ0005	Positive	1.29	J+J vaccinee serum - 1 dose
JJ0006	Positive	2.09	J+J vaccinee serum - 1 dose
JJ0007	Positive	1.19	J+J vaccinee serum - 1 dose
JJ0008	Positive	1.84	J+J vaccinee serum - 1 dose
JJ0009	Positive	0.57	J+J vaccinee serum - 1 dose
JJ0010	Positive	0.55	J+J vaccinee serum - 1 dose
JJ0011	Positive	1.68	J+J vaccinee serum - 1 dose